BDSX Biodesix Corporation: Year-over-year earnings per share growth for the last twelve months

Graphic logo of Biodesix, Inc. (BDSX)

Biodesix, Inc. (BDSX) generates revenue from the sale of non-invasive blood tests for oncologists and patients. Reviewing the quarterly EPS growth rate on GURU.Markets, it is evident that 35.60 describes the current status of the metric. Leadership in molecular lung diagnostics provides the company with access to the cancer analysis market. High sterile laboratory utilization and precise equipment calibration ensure compliance with medical standards.

BDSX: Biodesix Earnings per share growth in annualized terms for the last twelve months 07/04/2022 - 11/15/2026

Summary analytical data breakdowns for biodesix.com (BDSX)

- share price and expert price forecast:
Stock Price Biodesix Inc|BDSX - Analyst Consensus Forecast
- company stock capitalization data:
Market Value Biodesix|BDSX - Total Company Value
- book capitalization data:
Accounting Value per Share Biodesix|BDSX - Total Stockholders' Equity|Market Value to Book Value Ratio biodesix.com|BDSX - Company Total Asset Base
- debt burden and liquidity indicators:
Total Debt to Capital Biodesix, Inc.|BDSX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Biodesix Inc|BDSX - Company Total Debt Obligations|Debts to Book Capitalization Biodesix|BDSX - Company Long-Term Debt|Company Short-Term Debts Biodesix|Quick Liquidity biodesix.com
- earnings and valuation multiples information:
BDSX - Company Net Income|Projected Future Earnings Biodesix, Inc.|BDSX - Price to Earnings Multiple|Forward P/E Multiple Biodesix Inc|BDSX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biodesix Inc|BDSX - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Biodesix|BDSX - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months biodesix.com|BDSX - Earnings per share growth this year|Expected earnings per share growth for next year Biodesix, Inc.
- sales volume and revenue indicators:
BDSX - Company Sales Revenue|Projected Sales Volume Biodesix Corporation|BDSX - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Biodesix Inc|BDSX - Sales Growth YoY (Last 12 Months)
Analysis of all company metrics:Biodesix Corp - BDSX
Flagship merchandise of Biodesix, Inc.

This indicator measures the quarterly dynamics of earnings per share, allowing for the exclusion of one-time market distortions to identify the sustainability of fundamental growth. By analyzing historical quarterly EPS growth, an investor can assess how the scaling of Biodesix, Inc. (BDSX) rapid tests in oncology centers converts into actual revenue, which is critical for minimizing the risks of capital freeze within the biotech sector.

Direct competitors

Caris (CAI) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Guardant Corp (GH)|Year-over-year earnings per share growth for the last twelve months Veracyte, Inc.|Year-over-year earnings per share growth for the last twelve months CELC|Year-over-year net earnings per share growth for the last 12 months GRAL (GRAIL Bio)|MYGN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Castle Bio CSTL|Year-over-year net earnings per share change for the last twelve months Burning Rock Biotech Ltd (BNR)|VolitionRx Ltd. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months precipiodx.com PRPO|Check-Cap Ltd. (CHEK) - Year-over-year earnings per share growth for the last twelve months|MYNZ - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months OncoCyte Corporation